Abstract
Background and Purpose: GLORIA-AF is a large, global, prospective registry program of newly diagnosed atrial fibrillation (AF) patients with ≥1 stroke risk factors. We describe the effectiveness and safety of dabigatran etexilate over 2 years from routine clinical practice in nearly 3000 patients from GLORIA-AF who are newly diagnosed with non-valvular AF and at risk of stroke.
Methods: Consecutive enrollment into phase II of GLORIA-AF was initiated following approval of dabigatran for stroke prevention in non-valvular AF. Within this Phase II, 2937 dabigatran patients completed 2-year follow-up by May 2016 and were eligible for analysis. Patients who took at least 1 dose of dabigatran (n = 2932) were used to estimate incidence rates.
Results: Overall incidence rates per 100 person-years of 0.63 (95% confidence interval [CI], 0.42–0.92) for stroke, 1.12 (0.83–1.49) for major bleeding, 0.47 (0.29–0.72) for myocardial infarction, and 2.69 (2.22–3.23) for all-cause death were observed. For patients taking 150 mg dabigatran twice daily (BID), corresponding rates (95% CI) were 0.56 (0.30–0.94), 1.00 (0.64–1.47), 0.48 (0.25–0.83), and 2.07 (1.55–2.72), respectively. For patients taking 110 mg dabigatran BID, event rates (95% CI) were 0.67 (0.33–1.20), 1.16 (0.70–1.80), 0.43 (0.17–0.88), and 3.16 (2.36–4.15).
Conclusions: These global data confirm the sustained safety and effectiveness of dabigatran over 2 years of follow-up, consistent with the results from clinical trials as well as contemporary real-world studies.
Methods: Consecutive enrollment into phase II of GLORIA-AF was initiated following approval of dabigatran for stroke prevention in non-valvular AF. Within this Phase II, 2937 dabigatran patients completed 2-year follow-up by May 2016 and were eligible for analysis. Patients who took at least 1 dose of dabigatran (n = 2932) were used to estimate incidence rates.
Results: Overall incidence rates per 100 person-years of 0.63 (95% confidence interval [CI], 0.42–0.92) for stroke, 1.12 (0.83–1.49) for major bleeding, 0.47 (0.29–0.72) for myocardial infarction, and 2.69 (2.22–3.23) for all-cause death were observed. For patients taking 150 mg dabigatran twice daily (BID), corresponding rates (95% CI) were 0.56 (0.30–0.94), 1.00 (0.64–1.47), 0.48 (0.25–0.83), and 2.07 (1.55–2.72), respectively. For patients taking 110 mg dabigatran BID, event rates (95% CI) were 0.67 (0.33–1.20), 1.16 (0.70–1.80), 0.43 (0.17–0.88), and 3.16 (2.36–4.15).
Conclusions: These global data confirm the sustained safety and effectiveness of dabigatran over 2 years of follow-up, consistent with the results from clinical trials as well as contemporary real-world studies.
| Original language | English |
|---|---|
| Journal | American Heart Journal |
| Early online date | 31 Aug 2017 |
| DOIs | |
| Publication status | E-pub ahead of print - 31 Aug 2017 |